Jonathan D Cooper1. 1. Pediatric Storage Disorders Laboratory, Department of Neuropathology P040, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK. j.cooper@iop.kcl.ac.uk
Abstract
PURPOSE OF REVIEW: The identification of genes mutated in the neuronal ceroid lipofuscinoses has accelerated research into the mechanisms that underlie these fatal autosomal recessive storage disorders, which are often referred to as Batten disease. This review summarizes progress in this field since October 2001, describing advances in cell biology, the characterization of new animal models of neuronal ceroid lipofuscinosis, and the impact of novel methodology to reveal insights into its pathogenesis. RECENT FINDINGS: Gene products for six of the eight forms of neuronal ceroid lipofuscinosis have now been discovered, and concerted efforts are underway to understand the normal biology of each gene product and how this may be altered by mutation. Several lines of evidence point to functions for the CLN genes in the endosomal-lysosomal system, and suggest neuron-specific roles for these proteins. Indeed, a requirement for appropriate protein trafficking within neurons may explain the profound and selective effects of these disorders upon the central nervous system. The development of mouse and large animal models has enabled comparative studies of the progressive effects of disease, including characterization by morphological and biochemical means supplemented by metabonomic and microarray techniques. SUMMARY: Insights into disease mechanisms are building a detailed profile of the impact of neuronal ceroid lipofuscinosis upon the brain. With the eventual aim of developing successful therapeutic strategies, it will be equally important to characterize the clinical progression of the disorder, and to identify quantifiable endpoints that can ultimately be used in clinical trials.
PURPOSE OF REVIEW: The identification of genes mutated in the neuronal ceroid lipofuscinoses has accelerated research into the mechanisms that underlie these fatal autosomal recessive storage disorders, which are often referred to as Batten disease. This review summarizes progress in this field since October 2001, describing advances in cell biology, the characterization of new animal models of neuronal ceroid lipofuscinosis, and the impact of novel methodology to reveal insights into its pathogenesis. RECENT FINDINGS: Gene products for six of the eight forms of neuronal ceroid lipofuscinosis have now been discovered, and concerted efforts are underway to understand the normal biology of each gene product and how this may be altered by mutation. Several lines of evidence point to functions for the CLN genes in the endosomal-lysosomal system, and suggest neuron-specific roles for these proteins. Indeed, a requirement for appropriate protein trafficking within neurons may explain the profound and selective effects of these disorders upon the central nervous system. The development of mouse and large animal models has enabled comparative studies of the progressive effects of disease, including characterization by morphological and biochemical means supplemented by metabonomic and microarray techniques. SUMMARY: Insights into disease mechanisms are building a detailed profile of the impact of neuronal ceroid lipofuscinosis upon the brain. With the eventual aim of developing successful therapeutic strategies, it will be equally important to characterize the clinical progression of the disorder, and to identify quantifiable endpoints that can ultimately be used in clinical trials.
Authors: Charles V Mobbs; Kelvin Yen; Jason Mastaitis; Ha Nguyen; Elizabeth Watson; Elisa Wurmbach; Stuart C Sealfon; Andrew Brooks; Stephen R J Salton Journal: Neurochem Res Date: 2004-06 Impact factor: 3.996
Authors: Attila D Kovács; Angelika Saje; Andrew Wong; Gábor Szénási; Péter Kiricsi; Eva Szabó; Jonathan D Cooper; David A Pearce Journal: Neuropharmacology Date: 2010-10-29 Impact factor: 5.250
Authors: Elisabeth A de Blieck; Erika F Augustine; Frederick J Marshall; Heather Adams; Jennifer Cialone; Leon Dure; Jennifer M Kwon; Nicole Newhouse; Katherine Rose; Paul G Rothberg; Amy Vierhile; Jonathan W Mink Journal: Contemp Clin Trials Date: 2013-04-26 Impact factor: 2.226
Authors: Tony Frugier; Nadia L Mitchell; Imke Tammen; Peter J Houweling; Donald G Arthur; Graham W Kay; Otto P van Diggelen; Robert D Jolly; David N Palmer Journal: Neurobiol Dis Date: 2007-09-29 Impact factor: 5.996
Authors: Katherine A Borkovich; Lisa A Alex; Oded Yarden; Michael Freitag; Gloria E Turner; Nick D Read; Stephan Seiler; Deborah Bell-Pedersen; John Paietta; Nora Plesofsky; Michael Plamann; Marta Goodrich-Tanrikulu; Ulrich Schulte; Gertrud Mannhaupt; Frank E Nargang; Alan Radford; Claude Selitrennikoff; James E Galagan; Jay C Dunlap; Jennifer J Loros; David Catcheside; Hirokazu Inoue; Rodolfo Aramayo; Michael Polymenis; Eric U Selker; Matthew S Sachs; George A Marzluf; Ian Paulsen; Rowland Davis; Daniel J Ebbole; Alex Zelter; Eric R Kalkman; Rebecca O'Rourke; Frederick Bowring; Jane Yeadon; Chizu Ishii; Keiichiro Suzuki; Wataru Sakai; Robert Pratt Journal: Microbiol Mol Biol Rev Date: 2004-03 Impact factor: 11.056
Authors: Catherine Kielar; Thomas M Wishart; Alice Palmer; Sybille Dihanich; Andrew M Wong; Shannon L Macauley; Chun-Hung Chan; Mark S Sands; David A Pearce; Jonathan D Cooper; Thomas H Gillingwater Journal: Hum Mol Genet Date: 2009-07-29 Impact factor: 6.150